Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
Clinical trial NCT03326674 · TERMINATED
Trial details
- NCT number
- NCT03326674
- Sponsor
- Odonate Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-21
- Primary completion
- 2020-08-24
- Enrollment
- 685
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.